Novavax expects 2026 adjusted revenue between $185 million and $205 million, excluding royalties and sales from its licensing ...
Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a ...
Novavax on Thursday provided preliminary adjusted revenue for 2026 and pushed back its profitability target by a year to 2028 ...
Novavax says its COVID-19 vaccine is proving safe and effective for kids as young as 12. The Maryland-based company makes a protein-based vaccine that's been cleared for use in adults in parts of the ...
The Biden administration announced Monday that it would purchase 3.2 million doses of the Novavax COVID-19 vaccine. It will be offered at no cost to states and federal partners. “We remain committed ...
Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the U.S. marketing authorization for its COVID-19 vaccine, ...
Q3 2025 Earnings Call Transcript November 6, 2025 Novavax, Inc. misses on earnings expectations. Reported EPS is $-1.24654 ...
Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date ...
The COVID-19 vaccine rollout in 2025 is shaping up to be significant different than in past years. The U.S. Food and Drug Administration has approved updated vaccines under new guidelines, but the U.S ...
NEW YORK — Americans headed to pharmacies for covid-19 vaccines are running into roadblocks and confusion due to new U.S. guidance that abandoned broad support for the shots, contributing to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback